Paratek Pharmaceuticals of Boston announced it has closed the first tranche of a $40 million financing round. (It’s a Series H round, according to peHUB.) The company says it will use the funds in part to further the development of antibiotics to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
